UK markets close in 4 hours 4 minutes
  • FTSE 100

    7,102.09
    -66.59 (-0.93%)
     
  • FTSE 250

    22,683.27
    -229.46 (-1.00%)
     
  • AIM

    1,190.19
    -5.86 (-0.49%)
     
  • GBP/EUR

    1.1742
    +0.0017 (+0.15%)
     
  • GBP/USD

    1.3322
    +0.0045 (+0.34%)
     
  • BTC-GBP

    42,177.12
    -997.55 (-2.31%)
     
  • CMC Crypto 200

    1,434.39
    -34.69 (-2.36%)
     
  • S&P 500

    4,513.04
    -53.96 (-1.18%)
     
  • DOW

    34,022.04
    -461.68 (-1.34%)
     
  • CRUDE OIL

    65.75
    +0.18 (+0.27%)
     
  • GOLD FUTURES

    1,778.70
    -5.60 (-0.31%)
     
  • NIKKEI 225

    27,753.37
    -182.25 (-0.65%)
     
  • HANG SENG

    23,788.93
    +130.01 (+0.55%)
     
  • DAX

    15,232.59
    -240.08 (-1.55%)
     
  • CAC 40

    6,793.00
    -88.87 (-1.29%)
     

New composition of the management board of BioPorto A/S

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

November 19, 2021
Announcement no. 22

New composition of the management board of BioPorto A/S

With reference to announcement nos. 16 and 17 regarding the appointment of Anthony Pare and Neil A. Goldman as, respectively, new CEO and CFO of BioPorto A/S (“BioPorto”), the Board of Directors is pleased to announce that they both will join the management board of BioPorto with effect from 20 November 2021. Simultaneously, Peter Mørch Eriksen will step down from the management board, but will continue to support the company both on a full time basis until end of January 2022 and as a member of the Board of Directors.

For further information, please contact:

Tim Eriksen, Investor relations, BioPorto A/S, +45 61 68 77 79
e-mail: investor@bioporto.com

About BioPorto

BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].

Attachment


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting